Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Motesanib

Drug Profile

Motesanib

Alternative Names: AMG-706; Motesanib diphosphate

Latest Information Update: 14 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Takeda Bio Development Center
  • Class Amides; Antineoplastics; Indoles; Nicotinic acids; Pyridines; Small molecules
  • Mechanism of Action Platelet-derived growth factor receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Gastrointestinal stromal tumours; Non-small cell lung cancer; Thyroid cancer

Most Recent Events

  • 21 Sep 2020 Biomarkers information updated
  • 19 May 2015 Discontinued - Phase-III for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) in Taiwan, South Korea, Hong Kong, Japan (PO)
  • 17 Feb 2015 Takeda Pharmaceuticals terminates the MONET-A phase III trial in Non-small cell lung cancer (advanced disease, combination therapy) in Japan, South Korea, Taiwan, Hong Kong
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top